From NKT Therapeutics Aims For Severe Asthma, Targeting Natural Killer T Cells:

NKT logo—

NKT Therapeutics is developing drugs that target a class of immune cells known as natural killer T cells.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
How to Approach Life Sciences Fundraising
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex

Xconomy on Demand

We offer a number of ways to subscribe for free!